Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentration predict response to therapy in patients with rheumatoid arthritis

E.N. van Roon; T.L.T.A. Jansen; M.A.F.J. van de Laar; M. Janssen; J.P. Yska; R. Keuper; P.M. Houtman; J.R.B.J. Brouwers

doi:10.1136/ard.2004.025205

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentration predict response to therapy in patients with rheumatoid arthritis

E.N. van Roon, T.L.T.A. Jansen, M.A.F.J. van de Laar, M. Janssen, J.P. Yska, R. Keuper, P.M. Houtman, J.R.B.J. Brouwers

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	569-574
Journal	Annals of the rheumatic diseases
Volume	64
Issue number	4
DOIs	https://doi.org/10.1136/ard.2004.025205
Publication status	Published - 2004

Access to Document

10.1136/ard.2004.025205

Cite this

van Roon, E. N., Jansen, T. L. T. A., van de Laar, M. A. F. J., Janssen, M., Yska, J. P., Keuper, R., Houtman, P. M., & Brouwers, J. R. B. J. (2004). Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentration predict response to therapy in patients with rheumatoid arthritis. Annals of the rheumatic diseases, 64(4), 569-574. https://doi.org/10.1136/ard.2004.025205

@article{fe985cb4529141ebb5f6d0fae3af22c7,

title = "Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentration predict response to therapy in patients with rheumatoid arthritis",

author = "{van Roon}, E.N. and T.L.T.A. Jansen and {van de Laar}, M.A.F.J. and M. Janssen and J.P. Yska and R. Keuper and P.M. Houtman and J.R.B.J. Brouwers",

year = "2004",

doi = "10.1136/ard.2004.025205",

language = "English",

volume = "64",

pages = "569--574",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ",

number = "4",

}

van Roon, EN, Jansen, TLTA, van de Laar, MAFJ, Janssen, M, Yska, JP, Keuper, R, Houtman, PM & Brouwers, JRBJ 2004, 'Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentration predict response to therapy in patients with rheumatoid arthritis', Annals of the rheumatic diseases, vol. 64, no. 4, pp. 569-574. https://doi.org/10.1136/ard.2004.025205

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide : serum concentration predict response to therapy in patients with rheumatoid arthritis. / van Roon, E.N.; Jansen, T.L.T.A.; van de Laar, M.A.F.J. et al.

In: Annals of the rheumatic diseases, Vol. 64, No. 4, 2004, p. 569-574.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide

T2 - serum concentration predict response to therapy in patients with rheumatoid arthritis

AU - van Roon, E.N.

AU - Jansen, T.L.T.A.

AU - van de Laar, M.A.F.J.

AU - Janssen, M.

AU - Yska, J.P.

AU - Keuper, R.

AU - Houtman, P.M.

AU - Brouwers, J.R.B.J.

PY - 2004

Y1 - 2004

U2 - 10.1136/ard.2004.025205

DO - 10.1136/ard.2004.025205

M3 - Article

VL - 64

SP - 569

EP - 574

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

SN - 0003-4967

IS - 4

ER -